Company / R&D per Share
GeneDx Holdings Corp. R&D per Share History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$2.57
FY2025
5-year range
$1.76 / $848080.65
FY2021-FY2025
Trend
+46.1%
vs FY2024
Sector context
#36 of 103
Health Care
What the data says
At $2.57, GeneDx Holdings Corp.'s r&d per share ranks #36 of 103 in the Health Care sector. R&D per Share returned to growth in FY2025 after 3 years of decline, reaching $2.57.
Based on SEC 10-K filings.
2.57 in FY2025 with a 5-year CAGR of -82.1%.
Declined from $4.95 to $2.57 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- -94.7%
- 5-Year CAGR
- -82.1%
- 10-Year CAGR
- -
Sector benchmark
#36 of 103 in Health CareTop 35% of 103This company $2.57 Sector average $2.13
▼
+20.6% above sector average
Key checks
Key Insights
- In FY2025, r&d per share increased 46.1% year-over-year.
- Ranks #36 out of 103 companies in the Health Care sector.
- Peak r&d per share was recorded in FY2021.
- Lowest r&d per share in the period was in FY2024.
Company context
Key Data Points
- Altman Z-Score -0.67 (distress zone, below 1.8 threshold)
- Negative profit margin: -17.1%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.57 | +46.1% |
| FY2024 | $1.76 | -64.4% |
| FY2023 | $4.95 | -100.0% |
| FY2022 | $16800.43 | -98.0% |
| FY2021 | $848080.65 | +5885.6% |
| FY2020 | $14168.78 | -95.0% |
| FY2019 | $281532.26 | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026